DE60039730D1 - Genetisch manipulierte Herpesviren zur Behandlung von Tumoren - Google Patents

Genetisch manipulierte Herpesviren zur Behandlung von Tumoren

Info

Publication number
DE60039730D1
DE60039730D1 DE60039730T DE60039730T DE60039730D1 DE 60039730 D1 DE60039730 D1 DE 60039730D1 DE 60039730 T DE60039730 T DE 60039730T DE 60039730 T DE60039730 T DE 60039730T DE 60039730 D1 DE60039730 D1 DE 60039730D1
Authority
DE
Germany
Prior art keywords
herpesviruses
tumors
treatment
genetically manipulated
genetically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60039730T
Other languages
English (en)
Inventor
Ralph Weichselbaum
Bernard Roizman
Richard Whitley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
UAB Research Foundation
Original Assignee
Arch Development Corp
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp, UAB Research Foundation filed Critical Arch Development Corp
Application granted granted Critical
Publication of DE60039730D1 publication Critical patent/DE60039730D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60039730T 1999-02-05 2000-02-04 Genetisch manipulierte Herpesviren zur Behandlung von Tumoren Expired - Lifetime DE60039730D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24474899A 1999-02-05 1999-02-05

Publications (1)

Publication Number Publication Date
DE60039730D1 true DE60039730D1 (de) 2008-09-11

Family

ID=22923971

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60027870T Expired - Lifetime DE60027870T2 (de) 1999-02-05 2000-02-04 Genetische manipulierte herpesviren zur behandlung von tumoren
DE60039730T Expired - Lifetime DE60039730D1 (de) 1999-02-05 2000-02-04 Genetisch manipulierte Herpesviren zur Behandlung von Tumoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60027870T Expired - Lifetime DE60027870T2 (de) 1999-02-05 2000-02-04 Genetische manipulierte herpesviren zur behandlung von tumoren

Country Status (10)

Country Link
US (3) US20030207829A9 (de)
EP (2) EP1695714B1 (de)
JP (1) JP4623832B2 (de)
AT (2) ATE402713T1 (de)
AU (2) AU772471B2 (de)
CA (1) CA2361892C (de)
DE (2) DE60027870T2 (de)
DK (1) DK1695714T3 (de)
ES (2) ES2263454T3 (de)
WO (1) WO2000045853A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
MXPA01010393A (es) 1999-04-15 2004-04-02 Pro Virus Inc Tratamiento de neoplasmas con virus.
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002307749A1 (en) * 2001-05-09 2002-11-25 M's Science Corporation Composition and method for treating cancer using herpes virus
EP1487983A4 (de) * 2002-03-01 2007-08-15 Sloan Kettering Inst Cancer Verhinderung des wiederauftretens und der metastasierung von krebs
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
EP1549339B1 (de) 2002-10-07 2019-06-05 University Of Chicago Targeting von herpes simplex virus an spezifische rezeptoren
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US7731952B2 (en) * 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2008141151A2 (en) * 2007-05-09 2008-11-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
WO2009148488A2 (en) * 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
KR20180027516A (ko) * 2015-06-11 2018-03-14 유니버시티 오브 마이애미 암 치료 및 진단
WO2017181420A1 (en) * 2016-04-22 2017-10-26 Immuno Vir Co., Limited CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY
TWI666321B (zh) * 2017-10-23 2019-07-21 大陸商深圳市亦諾微醫藥科技有限公司 用於癌症治療的溶瘤性單純皰疹病毒（ｏＨＳＶ）專性載體及其建構體的建構
KR101974169B1 (ko) * 2018-08-10 2019-04-30 의료법인 성광의료재단 재조합 단순 헤르페스 바이러스 및 이의 제조방법
CA3150917A1 (en) * 2019-08-16 2021-02-25 Immvira Co., Limited Pharmaceutical compositions comprising oncolytic herpes simplex virus for systemic administration
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
JP7235334B2 (ja) * 2020-11-26 2023-03-08 イムヴィラ・カンパニー・リミテッド 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス（ｏＨＳＶ）偏性ベクター及びその構築体の構築

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5288641A (en) * 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5068192A (en) * 1986-01-27 1991-11-26 Prutech Research And Development Partnership Attenuated pseudorabies virus which includes foreign DNA encoding an amino acid sequence
US4999296A (en) * 1986-04-29 1991-03-12 Novagene, Inc. Thymidine kinase negative insertion mutants of pseudorabies virus and methods for the production of same
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5360893A (en) * 1992-07-20 1994-11-01 University Of Colorado Foundation, Inc. DNA sequences encoding proteins used to elicit and detect programmed cell death
US5593879A (en) * 1993-01-15 1997-01-14 Massachusetts Institute Of Technology Cell death genes of Drosophila melanogaster and vertebrate analogs
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
DE69722608T2 (de) * 1996-01-25 2004-04-29 The University Court Of The University Of Glasgow, Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
CA2200633A1 (en) * 1997-03-21 1998-09-21 Yuman Fong Rapid production of autologous tumor vaccines

Also Published As

Publication number Publication date
US8318691B2 (en) 2012-11-27
DK1695714T3 (da) 2008-11-10
WO2000045853A3 (en) 2001-05-31
US8772261B2 (en) 2014-07-08
AU2980000A (en) 2000-08-25
ATE325615T1 (de) 2006-06-15
ES2263454T3 (es) 2006-12-16
AU2004203458A1 (en) 2004-08-26
JP4623832B2 (ja) 2011-02-02
EP1695714A1 (de) 2006-08-30
DE60027870T2 (de) 2006-12-28
AU772471B2 (en) 2004-04-29
US20110002890A1 (en) 2011-01-06
CA2361892A1 (en) 2000-08-10
WO2000045853A2 (en) 2000-08-10
ATE402713T1 (de) 2008-08-15
US20130039890A1 (en) 2013-02-14
EP1695714B1 (de) 2008-07-30
DE60027870D1 (de) 2006-06-14
JP2002536347A (ja) 2002-10-29
US20030207829A9 (en) 2003-11-06
CA2361892C (en) 2010-05-25
EP1150696B1 (de) 2006-05-10
AU2004203458B2 (en) 2007-05-17
ES2310382T3 (es) 2009-01-01
US20020019362A1 (en) 2002-02-14
EP1150696A2 (de) 2001-11-07

Similar Documents

Publication Publication Date Title
DE60039730D1 (de) Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
ATE371372T1 (de) Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren
DE69940488D1 (de) Lichtquelle zur photodynamischen Therapie
CY1112425T1 (el) Αντισωματα αντι-ngf για την θεραπευτικη αγωγη διαφορων διαταραχων
DE69733834D1 (de) Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren
ATE240744T1 (de) Verwendung von csf-1-inhibitoren
DK0380230T3 (da) Immunogene sammensætninger mod gastrin-peptider
ATE458500T1 (de) Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
ATE241994T1 (de) Hsv-mutant-1716 zur behandlung von mesotheliomen
ATE306281T1 (de) Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
ATE316134T1 (de) Zusammensetzung mit alpha-glycosylceramid zur stärkung zellulärer immunogenität
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
DE69109283D1 (de) Verfahren zur sensibilisierung von tumorzellen.
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
ATE368649T1 (de) Cyanoguanidin prodrugs
MXPA02001204A (es) Compuestos calciliticos.
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
DK1140103T3 (da) Ponazuril til behandling af neurologiske og abortfremkaldende sygdomme forårsaget af Coccidia
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids
DE59911556D1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition